	US 11,981,734 B2
	Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)
Natalie Bezman, Foster City, CA (US); Alan J. Korman, Piedmont, CA (US); Shrikant Deshpande, Fremont, CA (US); Amy D. Jhatakia, Fremont, CA (US); Richard Y. Huang, Bridgewater, NJ (US); Guodong Chen, East Brunswick, NJ (US); Ginger C. Rakestraw, Somerville, MA (US); Karla Ann Henning, Milpitas, CA (US); Vangipuram S. Rangan, Pleasant Hill, CA (US); Christine Bee, San Francisco, CA (US); and Xiang Shao, Los Altos, CA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Filed by BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
Filed on Feb. 10, 2022, as Appl. No. 17/668,807.
Application 17/668,807 is a division of application No. 16/683,927, filed on Nov. 14, 2019, granted, now 11,274,150.
Claims priority of provisional application 62/927,211, filed on Oct. 29, 2019.
Claims priority of provisional application 62/768,471, filed on Nov. 16, 2018.
Prior Publication US 2022/0195042 A1, Jun. 23, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 1/22 (2006.01); C12N 5/071 (2010.01); C12N 15/85 (2006.01); C12P 21/00 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 1/22 (2013.01); C12N 5/0682 (2013.01); C12N 15/85 (2013.01); C12P 21/005 (2013.01); G01N 33/68 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C12N 2510/02 (2013.01); C12N 2800/107 (2013.01)]

163 Claims

1. An isolated nucleic acid molecule encoding an antibody, or antigen-binding fragment thereof, that binds human natural killer cell inhibitory receptor group 2A protein (NKG2A) wherein said antibody comprises an heavy chain complementarity determining region 1 (HCDR1), an HCDR2 and an HCDR3 of a heavy chain variable region (VH) of the amino acid sequence of SEQ ID NO:8 and a light chain complementary determining region 1 (LCDR1), an LCDR2 and an LCDR3 of a light chain variable region (VL) of the amino acid sequence of SEQ ID NO:9.